INVIVYD, INC. (IVVD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 31.03M USD | Liabilities, Current |
| Cash and equivalents | 160.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 11.22M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $31.03M | $160.08M | (m) | $11.22M | (m) | (m) |
| 2026-03-31 | (m) | $31.66M | $184.15M | (m) | $11.65M | (m) | (m) |
| 2025-12-31 | (m) | $34.16M | $226.69M | (m) | $13.92M | (m) | (m) |
| 2025-09-30 | (m) | $44.50M | $84.97M | (m) | $9.85M | $25.39M | (m) |
| 2025-06-30 | (m) | $44.45M | $34.91M | (m) | $8.70M | $25.44M | (m) |
| 2025-03-31 | (m) | $49.59M | $48.08M | (m) | $8.56M | $25.42M | (m) |
| 2024-12-31 | (m) | $61.98M | $69.35M | (m) | $10.91M | $25.91M | (m) |
| 2024-09-30 | (m) | $78.54M | $106.87M | (m) | $8.15M | $27.07M | (m) |
| 2024-06-30 | (m) | $36.70M | $147.88M | (m) | $2.89M | $5.33M | (m) |
| 2024-03-31 | (m) | $36.34M | $189.39M | (m) | (m) | $109.00K | (m) |
| 2023-12-31 | (m) | $50.29M | $200.64M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $26.79M | $181.82M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $32.51M | $121.95M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $22.06M | $126.47M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $25.03M | $92.08M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $46.13M | $278.15M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $67.88M | $474.88M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $95.53M | $532.22M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $62.06M | $542.22M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $53.05M | $478.27M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $37.90M | $392.51M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $13.07M | $114.99M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |